YILI CHUANNING BIOTECHNOLOGY CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.34 CNY | +2.14% |
|
-3.61% | +58.81% |
| Sales 2024 * | 5.65B 778M 1.07B | Sales 2025 * | 6.31B 869M 1.19B | Capitalization | 29.71B 4.09B 5.6B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.31B 181M 248M | Net income 2025 * | 1.56B 215M 294M | EV / Sales 2024 * | 5.26 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 4.71 x |
| P/E ratio 2024 * |
22.6
x | P/E ratio 2025 * |
19.1
x | Employees | 2,881 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 12.91% |
More Fundamentals
* Assessed data
More news
| 1 day | +2.14% | ||
| 1 week | -3.61% | ||
| Current month | +0.30% | ||
| 1 month | -12.64% | ||
| 3 months | +39.25% | ||
| 6 months | +58.06% | ||
| Current year | +58.81% |
1 week
12.74
13.90
1 month
12.7414.88
Current year
6.9418.33
1 year
6.9418.33
3 years
6.9418.33
5 years
6.9418.33
10 years
6.9418.33
| Managers | Title | Age | Since |
|---|---|---|---|
Xu Heng Deng
CEO | Chief Executive Officer | 37 | 20-06-17 |
Fan Yang
CHM | Chairman | 44 | 10-12-31 |
Yi Xing Li
DFI | Director of Finance/CFO | 40 | 13-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ge Xin Liu
CHM | Chairman | 73 | 20-06-17 |
Si Chuan Liu
BRD | Director/Board Member | 40 | 20-06-17 |
Xu Heng Deng
CEO | Chief Executive Officer | 37 | 20-06-17 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-21 | 13.34 | +2.14% | 45,469,010 |
| 24-06-20 | 13.06 | -3.69% | 46,353,510 |
| 24-06-19 | 13.56 | 0.00% | 33,326,500 |
| 24-06-18 | 13.56 | +1.80% | 40,962,100 |
| 24-06-17 | 13.32 | -3.76% | 58,779,260 |
End-of-day quote Shenzhen S.E., June 20, 2024
More quotes
Yili Chuanning Biotechnology Co Ltd is a China-based company mainly engaged in the research, development and industrialization of biological fermentation technology. The Company's products mainly include erythromycin thiocyanate, cephalosporin intermediates, penicillin intermediates, crude ursodeoxycholic acid, coenzyme Q10 mycelium and others. The Company's products are mainly exported to countries such as India.
Sector
Pharmaceuticals
Calendar
2024-08-19
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
13.34
CNY
Average target price
10.6
CNY
Spread / Average Target
-20.54%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +58.81% | 4.09B | |
| +51.63% | 796B | |
| +41.51% | 628B | |
| -5.10% | 358B | |
| +19.90% | 331B | |
| +9.95% | 301B | |
| +17.66% | 244B | |
| +3.39% | 228B | |
| +10.75% | 214B | |
| +6.99% | 165B |
- Stock Market
- Equities
- 301301 Stock
